Тромбоцитарные антиагреганты в лечении и профилактике ишемического инсульта
https://doi.org/10.14412/2074-2711-2013-2456
Аннотация
В обзоре литературы приведены современные представления о роли антитромбоцитарной терапии в лечении и вторичной профилактике ишемического инсульта. На основе данных доказательной медицины представлена аналитическая характеристика всех тромбоцитарных антиагрегантов, прошедших клинические испытания в мире. Продемонстрированы преимущества и несовершенства каждого средства как в монотерапии, так и при комбинированном использовании. Изложены основные принципы выбора антитромбоцитарных средств для пациентов в остром периоде и после ишемического инсульта.
Список литературы
1. <div><p>Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза. Клинические рекомендации ВНОК. Кардиоваскулярная терапия и профилактика. 2009;8(6). Приложение 3. [Diagnostika i korrektsiya narusheniy lipidnogo obmena s tsel'yu profilaktiki i lecheniya ateroskleroza. Klinicheskie rekomendatsii VNOK. Kardiovaskulyarnaya terapiya i profilaktika. 2009;8(6). Prilozhenie 3.]</p><p>Суслина ЗА, Гераскина ЛА, Фонякин А.. Артериальная гипертония и инсульт: связь и перспективы профилактики. Атмосфера. Кардиология 2001;1:5–7. [Suslina ZA, Geraskina LA, Fonyakin A.. Arterial'naya gipertoniya i insul't: svyaz' i perspektivy profilaktiki. Atmosfera. Kardiologiya 2001;1:5–7.]</p><p>Антитромботическая терапия у больных со стабильными проявлениями атеротромбоза. Российские рекомендации. Кардиоваскулярная терапия и профилактика. 2009;8 приложение 6:20. [Antithromlotic therapy in patients with stable manifestations of atherothrombosis. Russian advice. Kardiovaskulyarnaya terapiya i profilaktika. 2009;8 prilozhenie 6:20.]</p><p>Matias-Guiu J, Ferro JM, Alvarez-Sabin J et al. Comparison of triflusal and aspirin for prevention of vascular events in patients after cerebral infarction. The TACIP study: a randomized, double-blind, multicenter trial. Stroke. 2003;34(4):840–8. DOI: http://dx.doi.org/10.1161%2F01.STR.0000063141.24491.50. Epub 2003 Mar 20.</p><p>Costa J, Ferro JM, Matias-Guiu J et al. Trifluzal for preventing serious vascular events in people at high risk. Stroke. 2006;37;2193–5. DOI: http://dx.doi.org/10.1002%2F14651858.CD004296.</p><p>Huang Y, Cheng Y, Wu J et al. Cilostazol as an alternative to aspirin after ischaemic stroke: a randomized double blind pilot study. Lancet Neurol. 2008;7(6):494–9. DOI: 10.1016/S1474-4422(08)70094-2. Epub 2008 May 2.</p><p>Shinohara Y, Nishimaru K, Sawada T et al. Sarpogrelate-aspirin comparative clinical study for efficacy and safety in secondary prevention of cerebral infarction (C-ACCES). Stroke. 2008;39(6):1827–33. DOI: 10.1161/STROKEAHA.107.505131. Epub 2008 Apr 3.</p><p>CAST (Chinese Acute Stroke Trial) Collaborative Group. CAST: randomized placebo-controlled trial of early aspirin use in 20,000 patients with acute ischemic stroke. Lancet. 1997;349(9066):1641–9.</p><p>IST (International Stroke Trial) Collaborative Group. The International Stroke Trial (IST): a randomized trial of aspirin, subcutaneous heparin, both, or neither among 19,435 patients with acute ischemic stroke. Lancet. 1997;349:1569–81.</p><p>Chen ZM, Sandercock P, Pan HC et al. Indication for early aspirin use in acute ischemic stroke. A combined analysis of 40 000 randomized patients from the chines acute stroke trial and the international stroke trial. Stroke. 2000;31(6):1240–9.</p><p>The European Stroke Organization (ESO) Executive Committee and the ESO Writing Committee: Guidelines for management of ischaemic stroke and transient ischaemic attacks 2008. Cerebrovasc Dis. 2008;25(5):457–507. DOI: 10.1159/000131083. Epub 2008 May 6.</p><p>Furie KL, Kasner SE, Adams RJ et al. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack. AHA/ASA Guideline. Stroke. 2011;42(1):227–76. DOI: 10.1161/STR.0b013e3181f7d043. Epub 2010 Oct 21.</p><p>Antithrombotic Tralists` Collaboration. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction and stroke in high risk patients. BMJ. 2002;324(7329):71–86.</p><p>Суслина ЗА, Фонякин АВ, Гераскина ЛА. Ишемический инсульт и сердце: от патогенеза к профилактике. Клиническая фармакология и терапия. 2003;5:47–51. [Suslina ZA, Fonyakin AV, Geraskina LA. Ishemicheskiy insul't i serdtse: ot patogeneza k profilaktike. Klinicheskaya farmakologiya i terapiya. 2003;5:47–51.]</p><p>Фонякин АВ, Гераскина ЛА, Суслина ЗА. Сравнительная оценка постоянной и пароксизмальной фибрилляции предсердий в патогенезе кардиоцеребральной эмболии. Кардиология. 2002;7:4–6. [Fonyakin AV, Geraskina LA, Suslina ZA. Sravnitel'naya otsenka postoyannoy i paroksizmal'noy fibrillyatsii predserdiy v patogeneze kardiotserebral'noy embolii. Kardiologiya. 2002;7:4–6.]</p><p>Фонякин АВ, Гераскина ЛА, Суслина ЗА. Кардиальная патология при различных патогенетических подтипах ишемического инсульта. Клиническая медицина. 2002;1:25–8. [Fonyakin AV, Geraskina LA, Suslina ZA. Kardial'naya patologiya pri razlichnykh patogeneticheskikh podtipakh ishemicheskogo insul'ta. Klinicheskaya meditsina. 2002;1:25–8.]</p><p>Furie KL, Goldstein LB, Albers GW. et al. Oral antithrombotic agents for the prevention of stroke in nonvalvular atrial fibrillation: a science advisory for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2012;43(12):3442–53. DOI: 10.1161/STR.0b013e318266722a. Epub 2012 Aug 2.</p><p>Gent M., Blakely J.A., Easton J.D. et al. The Canadian American Ticlopidin Study (CATS) in thromboembolic stroke. Lancet. 1989;1:1215–20.</p><p>Hass WK, Easton JD, Adams HP et al. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients: Ticlopidin Aspirin Stroke Study Group. N Engl J Med. 1989;321(8):501–7.</p><p>Gorelick PB, Richardson D, Kelly M et al. Aspirin and ticlopidine for prevention of recurrent stroke in black patients: a randomized trial. JAMA. 2003;289(22):2947–57. DOI: http://dx.doi.org/10.1001%2Fjama.289.22.2947.</p><p>CAPRIE Steering Committee. A randomized, blinded trial of clopidogrel versus aspirin in patients at risk of ischemic events (CAPRIE). Lancet. 1996;348(9038):1329–39.</p><p>Bhatt DL, Fox KA, Hacke W et al. CHARISMA investigators: Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med. 2006;354(16):1706–17. Epub 2006 Mar 12.</p><p>Diener HC, Bogousslavsky J, Brass LM et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomized, double-blind, placebo-controlled trial. Lancet. 2004;364(9431):331–7.</p><p>Diener HC, Sacco RL, Yusuf S; Steering Committee; PROFESS Study Group. Rationale, design and baseline data of a randomized, double-blind, controlled trial comparing two Antithrombotic regimen (a fixed-dose combination of extended-release dipyridamole plus ASA with clopidogrel) and telmisartan versus placebo in patients with stroke. The Prevention Regimen for Effectively Avoiding Second Strokes Trial (PROFESS). Cerebrovasc Dis. 2007;23(5–6):368–80. Epub 2007 Feb 26.</p><p>Diener HC, Cunha L, Forbes C et al. European Stroke Prevention Study 2 (ESPS2). Dipyridaml and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci. 1996;143:1–13.</p><p>Kennedy J, Ryckborst KJ, Eliasziw M et al. Fast assessment of stroke and transient ischaemic attack to prevent early recurrence (FASTER): a randomised controlled pilot trial. Lancet Neurol. 2007;6(11):961–9. DOI: http://dx.doi.org/10.1016%2FS1474-4422%2807%2970250-8.</p><p>The Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) Trial Investigators. Effect of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345:494–502.</p><p>The ESPS Group. The European Stroke Prevention Study (ESPS): principal end-points. Lancet. 1987;2(8572):1351–4.</p><p>Verro P, Gorelick PB, Nguyen D. Aspirin plus dipiridamol versus aspirin for prevention of vascular events after stroke or TIA. Meta-analysis. Stroke. 2008;39(4):1358–63. DOI: 10.1161/STROKEAHA.107.496281. Epub 2008 Mar 6.</p><p>The ESPRIT study group. Aspirin plus dipyridamole versus aspirin alone after cerebral ischemia of arterial origin (ESPRIT): randomized controlled trial. Lancet. 2006;367(9523):1665–73.</p></div><br />
Рецензия
Для цитирования:
Fonyakin AV. Тромбоцитарные антиагреганты в лечении и профилактике ишемического инсульта. Неврология, нейропсихиатрия, психосоматика. 2013;5(4):54-59. https://doi.org/10.14412/2074-2711-2013-2456
For citation:
Fonyakin AV. Platelet antiaggregants in the treatment and prevention of ischemic stroke. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2013;5(4):54-59. (In Russ.) https://doi.org/10.14412/2074-2711-2013-2456
Просмотров:
1056
Послать статью по эл. почте 